Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Terminated × alovudine × Clear all

Phase

Phase NA 2 Phase 1/2 2 Phase 2 1 Phase 1 1

Status

Completed 7 Active not recruiting 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Disease 1 Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 88 pembrolizumab 69 Gemcitabine 65 fludarabine 55 Nivolumab 49 Carboplatin 48 Rituximab 43 Radiotherapy 42 Paclitaxel 42 Docetaxel 42 Cisplatin 41 Lenalidomide 35 Dexamethasone 35 Ipilimumab 33 Cytarabine 31 Radiation 28 Etoposide 28 Azacitidine 28 Temozolomide 26 venetoclax 25 Bevacizumab 24 Bortezomib 22 Pemetrexed 21 Capecitabine 21 Magnetic Resonance Spectroscopy 20 fludarabine phosphate 19 atezolizumab 19 Oxaliplatin 19 Interleukin-2 19 Everolimus 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00633958 2021-10-20

FLT

Dana-Farber Cancer Institute

Phase 1 Terminated

Disease, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡